-
[The “In China for Global”] approach not only ensures that we can provide effective treat-ments to Chinese patients but also unlocks the full potential of our drugs for a global au-dience.
September 11, 2024 -
New Gene Therapy Shows Potential for Safety, Efficacy in Mouse Model
May 11, 2022 -
China Biotech CEO Podcast: CANbridge’s Xue On Orphan Drug Coverage, Financing, Gene Therapy
27 Apr 2022
-
CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA
20240930 -
CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
20240819 -
CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics
20240807 -
CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease
20240708 -
CANbridge Announces Expansion of LIVMARLI® Label to Include Patients as Young as 3 Months in China
20240521 -
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023
20240328 -
CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base
20240301 -
Livmarli mentioned as a case study The Policy Address highlights Hong Kong's strengths in research and development, emphasizing its capcity to independently approve new drugs Rare disease drugs will receive significant benefits
20231115 -
Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully
20231106